Cell-free DNA and genetic testing company Natera Inc (NASDAQ: NTRA) announced on Monday that it has introduced the Prospera Heart test with Donor Quantity Score (DQS), improving the detection of rejection in heart transplant patients. This new feature enhances the ability to detect both acute cellular rejection (ACR) and antibody-mediated rejection (AMR).
Traditional donor-derived cell-free DNA (dd-cfDNA) tests rely on the percentage of dd-cfDNA in the blood, which can be affected by unrelated factors like infection or chemotherapy. The new DQS technique normalises these fluctuations by incorporating a second metric. Prospera Heart with DQS combines the traditional donor fraction and the DQS into a two-threshold algorithm, providing a more accurate risk assessment.
A study conducted at the University of Utah and the University of California San Diego demonstrated that incorporating DQS improves the performance of Prospera Heart in screening for biopsy-proven active rejection. In an analysis of 703 plasma samples, the sensitivity increased from 80.0% to 88.2%, specificity from 76.1% to 84.2%, and the negative predictive value (NPV) from 97.4% to 98.6%, reducing false positives by 37.5%.
These findings were presented at the International Society for Heart and Lung Transplantation's annual meeting in April 2024 and will be submitted for peer-reviewed publication.
The company has successfully applied a similar two-threshold approach in kidney transplant rejection tests with Prospera Kidney, published in the Journal of the American Society of Nephrology. The Prospera tests use single-nucleotide (SNP)-based massively multiplexed PCR (mmPCR) technology to identify allograft rejection non-invasively, without needing prior donor or recipient genotyping.
Natera focuses on oncology, women's health and organ health. The company operates ISO 13485-certified and CAP-accredited laboratories in Austin, Texas and San Carlos, California.
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Oxford BioDynamics announces distribution agreement with Regina Maria for EpiSwitch tests in Romania
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
Hoth Therapeutics and OnTargetx R&D partner on cancer research
CStone Pharmaceuticals' Cejemly included in ESMO NSCLC Living Guideline
TransCode Therapeutics enrols three patients in Cohort 3 of TTX-MC138 Phase 1 clinical trial
Biohit partners with Restalyst to enhance early gastric cancer detection
Henlius's serplulimab approved in Europe for Extensive-Stage Small Cell Lung Cancer
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Oxford BioDynamics reports high accuracy for blood-based colorectal cancer test
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer